
Perspective
New insights into huperzine A for the treatment of Alzheimer's disease
Hai-yan ZHANG*
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible
acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer’s disease (AD). Accordingly, some new mechanisms of action for huperzine A have been discovered over the past decades. In addition to its AChE inhibitory
effect, potent multifaceted neuroprotective effect through activating cholinergic system and directly acting on mitochondria have been explored. Moreover, in order to maximize the efficacy and safety of huperzine A therapy, great efforts have been made to optimize drug delivery system. In the present article, an attempt is made to discuss the current progress and future perspective for huperzine A therapy in AD.
Keywords: Alzheimer’s disease; huperzine A; acetylcholinesterase; mitochondrion; controlled release
Acta Pharmacologica Sinica (2012) 33: 1170–1175; doi: 10.1038/aps.2012.128; published online 3 Sep 2012
Alzheimer’s disease (AD) is a neurodegenerative dis-order characterized by gradually loss of memory and other cognitive functions. Understanding the complex-ity of AD and its underlying pathophysiological mecha-nisms of AD provides a potential new paradigm that may help to develop new AD treatment[1]. Among the limited therapeutic approaches, cholinergic replacement therapy especially acetylcholinesterase inhibitors (AChEIs), has been at the forefront of efforts to pharmacologically ame-liorate the symptom of AD patients. So far, four AChEIs, tacrine, donepezil, rivastigmine, and galantamine, have been approved by the United States Food and Drug Administration for the treatment of mild or moderate AD. Huperzine A is a novel Lycopodium alkaloid isolated from Chinese herb Huperzia serrata (Thunb) Trev (Qian Ceng Ta), which was traditionally used to relieve pain, antidote the poison, as well as alleviate swelling. Huperzine A is widely proved to be a potent, selective and well-tolerated inhibitor of acetylcholinesterase (AChE) (reviewed by[2]). This effect was accidentally discovered in the 1970s while herbal extraction of Huperzine serrata was used to treat schizophrenia and found with significant cholinergic side effects. Huperzine A was
* To whom correspondence should be addressed. E-mail hzhang@mail.shcnc.ac.cn
Received 2012-07-04 Accepted 2012-08-10
Introduction
approved by State Food and Drug Administration of China for AD therapy in 1994. Since then, large amount of clinical studies have shown that huperzine A administration can sig-nificantly improve the memory, cognitive skills, and daily life abilities of AD patients with no severe side effects. Besides being indicated for AD, huperzine A is also used in treating memory impairment in vascular dementia (VaD) patients, schizophrenia patients and sleep disorder in insomniacs (reviewed by[2]).
Suggestions on the multifaceted neuroprotective effects of huperzine A came from its superior preclinical and clinical benefits as compared with other clinically used AChEIs, and also from large numbers of laboratory studies evaluating the mechanisms of this compound (reviewed by[3]). This perspec-tive summarizes the evidences of novel insights of huperzine A to reduce AD risk, the molecular mechanisms involved in the anti-AD effects of huperzine A aside from its traditional AChE inhibition, and the novel delivery system which modi-fied release patterns of this drug.
Multifaceted pharmacological effects of huperzine A: cholinergic-dependent and -independent mechanism
Although we are still at the stage of symptomatic treatments for AD since AChEIs remains the most widely used drugs, we are moving into an age in which disease-modifying agents, particularly, drugs with potent neuroprotective effect are con-sidered to play a significant role in delaying AD development.
(-)-Huperzine A_102518-79-6_DataSheet_MedChemExpress_医药卫生_专业资料...New insights into huperzine A for the treatment of Alzheimer's disease. ...
(-)-Huperzine A_102518-79-6_DataSheet_MedChemExpress_医药卫生_专业资料。...New insights into huperzine A for the treatment of Alzheimer's disease. ...
(-)-Huperzine A_102518-79-6_DataSheet_MedChemExpress_医药卫生_专业资料。...New insights into huperzine A for the treatment of Alzheimer's disease. ...
(±)-Huperzine A_120786-18-7_DataSheet_MedChemExpress_医药卫生_专业资料...New insights into huperzine A for the treatment of Alzheimer's disease. ...
(±)-Huperzine A_120786-18-7_DataSheet_MedChemExpress_医药卫生_专业资料...New insights into huperzine A for the treatment of Alzheimer's disease. ...
Potent, Easily Synthesized Huperzine A-Tacrine ...treatment of Alzheimer's disease (AD). 2 ...The present work offers insights into crafting ...
DONEPEZIL A NEW CHO... 暂无评价 3页 免费 ... Novel insights for the... 2页 免费 Donepezil ... for the treatment of Alzheimer’s disease. ...
New insights into huperz... 暂无评价 6页 免费 Memantine Improves Spati..... rivastigmine and memantine for the treatment of Alzheimer’s disease Review ...
The results offer new insights into factors ...treatment of Alzheimer’s disease (AD).1 ...2, 2003 Structures of TcAChE with Huperzine A-...
Alzheimer's disease is a synaptic failure_生物...insights than are further studies of late-stage ...Conversely, treatment of the cells with an ...
热门文档